According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune ...

Estimated geographical and temporal distribution of lung-cancer incidence varied across the four main subtypes worldwide. Our ...

As monotherapy for treatment of adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations, after failure of platinum-based therapy.

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies.

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled "Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 ...

Cases of lung cancer in people who've never smoked cigarettes or tobacco are increasing, along with evidence suggesting air ...

Researchers found that, in patients with stage III NSCLC, treatment with cCRT and an ICI was safe, but treatment with cCRT and 2 ICIs led to “excessive mortality.” ...

Since the application of molecular biology in cancer biology, lung cancer research has classically focused on molecular drivers of disease. One such pathway, the hypoxic response pathway, is ...

EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...

D tumoroid models transform cancer research, accurately reflecting tumor biology and enabling effective drug testing and ...

The firms will evaluate two adjuvant treatment options, Datroway with rilvegostomig or rilvegostomig monotherapy, against standard-of-care treatment.

Table 1. Efficacy data from Phase II/III trials involving KRASG12C inhibitors sotorasib and adagrasib in pretreated advanced non-small cell lung cancer. Despite promising efficacy, resistance to ...